This trial is active, not recruiting.

Condition prostate cancer
Treatments docetaxel, avastin, lupron or zoladex, bicalutamide
Phase phase 2
Target VEGF
Sponsor Dana-Farber Cancer Institute
Collaborator Brigham and Women's Hospital
Start date April 2008
End date December 2014
Trial size 42 participants
Trial identifier NCT00658697, 08-004


In this research study, we are looking to see how Avastin works in combination with docetaxel and hormone therapy for men who have a rising PSA after treatment of their prostate cancer with surgery or radiation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Day#1: Docetaxel (75 mg/M2) q 3 weeks x 4 cycles (3 mo) Day#1: Avastin (15 mg/kg) q 3 wks x 8 cycles (6 mo) Day#1: LHRH agonist q 3 months x 6 doses (18 mo) Day #84: Bicalutamide (50mg) mo 4-18
Intravenously every three weeks for 4 cycles (total to 3 months)
Intravenously every 3 weeks for a total of 17 cycles (total of 1 year)
lupron or zoladex
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Starting on day 84 orally once daily until hormone therapy is completed

Primary Outcomes

Evaluate the proportion of patients free from PSA progression at one year off ADT.
time frame: 2 years

Secondary Outcomes

PSA response as completion of docetaxel/Avastin, at completion of ADT and one year off ADT
time frame: 2 years
Correlation of PSA response and TTP
time frame: 2 years
time frame: 2 years
Testosterone recovery at 6, 12 months off ADT
time frame: 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - 18 years of age or older - History of biopsy documented prostate cancer (any Gleason score) - Past treatment with prostatectomy with our without salvage prostate/pelvic radiation or primary radiation - If past prostatectomy, pathologic stage no greater than T1-3, N1, M0 - PSA recurrence with PSAdt 8 months or less. There is no minimum PSA for prostatectomy patients. For patients treated with primary radiation therapy PSA should be 2.0ng/ml or greater - No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis on CXR - Prior ADT allowed if less than 6 months and testosterone recovered to within 50 units of normal range - ECOG Performance status of 0-1 - Absolute neutrophil count of 1,500 mm3 or greater - Platelet Count 100,000 mm3 or greater - Total bilirubin within normal limits - HG 8gm/dl or greater - Testosterone within 50 units of normal range - No history of bleeding or thromboses within the last 12 months that required medical intervention Exclusion Criteria: - History of cancer within 5 years, other than prostate cancer and non-melanoma skin cancer - Medical condition requiring concomitant corticosteroids - Active infection - Prior chemotherapy - Neuropathy requiring medical therapy - Documented local recurrence or metastatic prostate cancer - Inability to comply with study and/or follow-up procedures - Life expectancy of less than 2 years - Current, recent (within 4 weeks of first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study - Inadequately controlled hypertension - Any prior history of hypertensive crisis or hypertensive encephalopathy - NYHA Grade II or greater congestive heart failure - History of myocardial infarction or unstable angina within 12 months prior to study enrollment - History of stroke or transient ischemic attack at any time - Known CNS disease - Significant vascular disease - Symptomatic peripheral vascular disease - Evidence of bleeding diathesis or coagulopathy - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study - Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrollment - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment - Serious, non-healing wound, ulcer, or bone fracture - Proteinuria at screening - Known hypersensitivity to any component of Avastin

Additional Information

Official title A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising PSA After Local Therapy
Principal investigator Mary-Ellen Taplin, MD
Description - Each treatment cycle lasts three weeks. During the first three months, participants will receive the Avastin and docetaxel on day 1 of each three-week cycle for a total of four doses of docetaxel/Avastin. Avastin and docetaxel are administered intravenously. The Avastin will continue to be given every three weeks after the docetaxel is completed for a total of 17 doses (one year) of Avastin therapy. - Participants will receive zoladex (or lupron) on day 1 of the first cycle and then every 3 months for a total of 18 months. Zoladex is administered subcutaneously and Lupron is administered intramuscularly. - Bicalutamide pills will be started at the completion of docetaxel chemotherapy (start of month 4) and will be taken once daily until hormone therapy is completed (total of 15 months). - During all treatment cycles, the participant will have a physical exam and will be asked questions about their general health and specific questions about any problems they might be experiencing. Blood work will be performed every three weeks for the first three months and then every three months while on hormone therapy and during follow-up. - After the final treatment participants will have a follow-up visit every three months for the first two years, every 4 months for the third year and every 6 months for years 4 and 5.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by Dana-Farber Cancer Institute.